Anti-Hypertensive Drugs - Romania

Romania

The Anti-Hypertensive Drugs market in Romania is projected to achieve a revenue of US$31.73m in the year 2024.
It is expected that this revenue will exhibit an annual growth rate (CAGR 2024-2029) of 0.19%, leading to a market volume of US$32.03m by the year 2029.
When compared to global figures, United States is anticipated to generate the highest revenue in this market, amounting to US$12,290.00m in the year 2024.
The demand for anti-hypertensive drugs in Romania has been steadily increasing due to the rising prevalence of hypertension among the population.

Key regions: Japan, India, Italy, Brazil, South Korea

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Hypertensive Drugs market in Romania has been experiencing steady growth in recent years.

Customer preferences: Romanians are becoming increasingly health-conscious and aware of the importance of managing hypertension, which has led to a growing demand for anti-hypertensive drugs. Patients are also seeking more convenient and effective treatment options, such as combination drugs and long-acting formulations.

Trends in the market: One major trend in the Romanian Anti-Hypertensive Drugs market is the increasing use of generic drugs. This is due to the government's cost-containment efforts and the expiration of patents for several major brands. As a result, many patients are switching to lower-cost generic alternatives. Another trend is the growing popularity of fixed-dose combination drugs, which offer more convenient and effective treatment options for patients.

Local special circumstances: The Romanian healthcare system is still in a state of transition, with ongoing efforts to improve access to care and modernize infrastructure. This has led to some challenges in terms of drug pricing and reimbursement, particularly for newer and more expensive medications. Additionally, there is a high prevalence of cardiovascular disease in Romania, which has contributed to the demand for anti-hypertensive drugs.

Underlying macroeconomic factors: Romania is a rapidly developing country with a growing middle class and an expanding healthcare sector. However, the country still faces some economic challenges, including high levels of poverty and inequality, which can impact access to healthcare. Additionally, the COVID-19 pandemic has had a significant impact on the Romanian economy and healthcare system, which may have implications for the Anti-Hypertensive Drugs market in the coming years.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.